Small cell carcinoma of the lung - Revision history

Michael at 13:54, 17 January 2025

2025-01-17T13:54:54Z

← Older revision		Revision as of 13:54, 17 January 2025
Line 5:		Line 5:
	\| Caption = Lung small cell carcinoma. [[H&E stain]].		\| Caption = Lung small cell carcinoma. [[H&E stain]].
	\| Synonyms =		\| Synonyms =
	\| Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, [[mitoses]]		\| Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, mitoses
	\| Subtypes = histology: large cell neuroendocrine carcinoma (LCNEC); molecular subtypes: ASCL1, NEUROD1, POU2F3, YAP1		\| Subtypes = histology: large cell neuroendocrine carcinoma (LCNEC); molecular subtypes: ASCL1, NEUROD1, POU2F3, YAP1
	\| LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]]		\| LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]] (e.g [[Ewing sarcoma]], [[NUT carcinoma]])
	\| Stains =		\| Stains =
	\| IHC = chromogranin +ve, synaptophysin +ve, CD56 +ve, NSE +ve, TTF-1 +ve, Ki-67 (>50%)		\| IHC = chromogranin +ve, synaptophysin +ve, CD56 +ve, NSE +ve, TTF-1 +ve, Ki-67 (>50%)

Michael: /* Molecular subtypes via IHC */

2025-01-16T22:49:29Z

Molecular subtypes via IHC

← Older revision		Revision as of 22:49, 16 January 2025
Line 118:		Line 118:
	! Notes		! Notes
	\|-		\|-
	\|ASCL1+ / NeuroD1-		\|ASCL1 +ve / NeuroD1 -ve
	\|41%		\|41%
	\|~~TTF1~~+		\|TTF-1 +ve
	\|		\|
	\|-		\|-
	\|ASCL1+ / NeuroD1+		\|ASCL1 +ve / NeuroD1 +ve
	\|37%		\|37%
	\|~~TTF1~~+		\|TTF-1 +ve
	\|		\|
	\|-		\|-
	\|ASCL1- / NeuroD1+		\|ASCL1 -ve / NeuroD1 +ve
	\|8%		\|8%
	\|~~TTF1~~+		\|TTF-1 +ve
	\|		\|
	\|-		\|-
	\|ASCL1- / NeuroD1-		\|ASCL1 -ve / NeuroD1 -ve
	\|14%		\|14%
	\|~~TTF1~~-		\|TTF-1 -ve
	\|includes all POU2F3+ cases which are ~9% of small cell carcinoma		\|includes all POU2F3 +ve cases which are ~9% of small cell carcinoma
	\|}		\|}

Michael: /* Molecular subtypes via IHC */

2025-01-16T22:47:22Z

Molecular subtypes via IHC

← Older revision		Revision as of 22:47, 16 January 2025
Line 136:		Line 136:
	\|14%		\|14%
	\|TTF1-		\|TTF1-
	\|includes all POU2F3 cases which are ~9% of small cell carcinoma		\|includes all POU2F3+ cases which are ~9% of small cell carcinoma
	\|}		\|}

Michael: /* Molecular subtypes via IHC */

2025-01-16T22:47:01Z

Molecular subtypes via IHC

← Older revision		Revision as of 22:47, 16 January 2025
Line 115:		Line 115:
	! IHC grouping		! IHC grouping
	! Prevalence		! Prevalence
			! Other IHC
	! Notes		! Notes
	~~! Other IHC~~
	\|-		\|-
	\|ASCL1+ / NeuroD1-		\|ASCL1+ / NeuroD1-
	\|41%		\|41%
			\|TTF1+
	\|		\|
	~~\|TTF1+~~
	\|-		\|-
	\|ASCL1+ / NeuroD1+		\|ASCL1+ / NeuroD1+
	\|37%		\|37%
			\|TTF1+
	\|		\|
	~~\|TTF1+~~
	\|-		\|-
	\|ASCL1- / NeuroD1+		\|ASCL1- / NeuroD1+
	\|8%		\|8%
			\|TTF1+
	\|		\|
	~~\|TTF1+~~
	\|-		\|-
	\|ASCL1- / NeuroD1-		\|ASCL1- / NeuroD1-
	\|14%		\|14%
			\|TTF1-
	\|includes all POU2F3 cases which are ~9% of small cell carcinoma		\|includes all POU2F3 cases which are ~9% of small cell carcinoma
	~~\|TTF1-~~
	\|}		\|}

Michael at 22:46, 16 January 2025

2025-01-16T22:46:08Z

← Older revision		Revision as of 22:46, 16 January 2025
Line 111:		Line 111:

	===Molecular subtypes via IHC===		===Molecular subtypes via IHC===
	Based on ~~Chiang~~ ''et al.'' in a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>		Based on Baine ''et al.'' in a cohort of ~170 cases:<ref name=pmid33011388>{{cite journal \|authors=Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N \|title=SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization \|journal=J Thorac Oncol \|volume=15 \|issue=12 \|pages=1823–1835 \|date=December 2020 \|pmid=33011388 \|pmc=8362797 \|doi=10.1016/j.jtho.2020.09.009 \|url=}}</ref>
	~~{\| class="wikitable sortable"~~
	~~!Type~~
	~~!Prevalence~~
	~~!Staining with IHC marker~~
	\|-
	~~\|ASCL1~~
	~~\| 55%~~
	~~\| 73%~~
	\|-
	~~\|NEUROD1~~
	~~\| 27%~~
	~~\| 63%~~
	\|-
	~~\|POU2F3~~
	~~\| 10%~~
	~~\| 15%~~
	\|-
	~~\|YAP1~~
	~~\| 0%~~
	~~\| 3%~~
	\|}

	~~Based on Baine ''et al.''~~:<ref name=pmid33011388>{{cite journal \|authors=Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N \|title=SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization \|journal=J Thorac Oncol \|volume=15 \|issue=12 \|pages=1823–1835 \|date=December 2020 \|pmid=33011388 \|pmc=8362797 \|doi=10.1016/j.jtho.2020.09.009 \|url=}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	! IHC grouping		! IHC grouping

Michael: /* Molecular subtypes via IHC */

2025-01-16T22:45:00Z

Molecular subtypes via IHC

← Older revision		Revision as of 22:45, 16 January 2025
Line 132:		Line 132:
	\| 0%		\| 0%
	\| 3%		\| 3%
			\|}

			Based on Baine ''et al.'':<ref name=pmid33011388>{{cite journal \|authors=Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N \|title=SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization \|journal=J Thorac Oncol \|volume=15 \|issue=12 \|pages=1823–1835 \|date=December 2020 \|pmid=33011388 \|pmc=8362797 \|doi=10.1016/j.jtho.2020.09.009 \|url=}}</ref>
			{\| class="wikitable sortable"
			! IHC grouping
			! Prevalence
			! Notes
			! Other IHC
			\|-
			\|ASCL1+ / NeuroD1-
			\|41%
			\|
			\|TTF1+
			\|-
			\|ASCL1+ / NeuroD1+
			\|37%
			\|
			\|TTF1+
			\|-
			\|ASCL1- / NeuroD1+
			\|8%
			\|
			\|TTF1+
			\|-
			\|ASCL1- / NeuroD1-
			\|14%
			\|includes all POU2F3 cases which are ~9% of small cell carcinoma
			\|TTF1-
	\|}		\|}

Michael: /* Molecular subtypes via IHC */

2025-01-16T22:43:35Z

Molecular subtypes via IHC

← Older revision		Revision as of 22:43, 16 January 2025
Line 111:		Line 111:

	===Molecular subtypes via IHC===		===Molecular subtypes via IHC===
	Based on a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>		Based on Chiang ''et al.'' in a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	!Type		!Type

Michael at 22:35, 16 January 2025

2025-01-16T22:35:11Z

← Older revision		Revision as of 22:35, 16 January 2025
Line 133:		Line 133:
	\| 3%		\| 3%
	\|}		\|}

			==Molecular==
			Four molecular subtypes - defined by the key transcriptional regulators:<ref>{{cite journal \|authors=Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF \|title=Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data \|journal=Nat Rev Cancer \|volume=19 \|issue=5 \|pages=289–297 \|date=May 2019 \|pmid=30926931 \|pmc=6538259 \|doi=10.1038/s41568-019-0133-9 \|url=}}</ref>
			*ASCL1 = achaete-scute homologue 1.
			*NeuroD1 = neurogenic differentiation factor 1.
			*YAP1 = yes-associated protein 1.
			*POU2F3 = POU class 2 homeobox 3.

	==Sign out==		==Sign out==

Michael at 22:29, 16 January 2025

2025-01-16T22:29:45Z

← Older revision		Revision as of 22:29, 16 January 2025
Line 111:		Line 111:

	===Molecular subtypes via IHC===		===Molecular subtypes via IHC===

	~~==Subtypes==~~
	Based on a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>		Based on a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Michael at 22:29, 16 January 2025

2025-01-16T22:29:23Z

← Older revision		Revision as of 22:29, 16 January 2025
Line 6:		Line 6:
	\| Synonyms =		\| Synonyms =
	\| Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, [[mitoses]]		\| Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, [[mitoses]]
	\| Subtypes = large cell neuroendocrine carcinoma (LCNEC)		\| Subtypes = histology: large cell neuroendocrine carcinoma (LCNEC); molecular subtypes: ASCL1, NEUROD1, POU2F3, YAP1
	\| LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]]		\| LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]]
	\| Stains =		\| Stains =

← Older revision		Revision as of 22:46, 16 January 2025
Line 111:		Line 111:

	===Molecular subtypes via IHC===		===Molecular subtypes via IHC===
	Based on ~~Chiang~~ ''et al.'' in a cohort of 72 small cell carcinomas:<ref>{{cite journal \|authors=Chiang CL, Huang HC, Luo YH, Shen CI, Chao HS, Tseng YH, Chou TY, Schrump DS, Yeh YC, Chen YM \|title=Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer \|journal=Lung Cancer \|volume=188 \|issue= \|pages=107473 \|date=February 2024 \|pmid=38232600 \|doi=10.1016/j.lungcan.2024.107473 \|url=}}</ref>		Based on Baine ''et al.'' in a cohort of ~170 cases:<ref name=pmid33011388>{{cite journal \|authors=Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N \|title=SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization \|journal=J Thorac Oncol \|volume=15 \|issue=12 \|pages=1823–1835 \|date=December 2020 \|pmid=33011388 \|pmc=8362797 \|doi=10.1016/j.jtho.2020.09.009 \|url=}}</ref>
	~~{\| class="wikitable sortable"~~
	~~!Type~~
	~~!Prevalence~~
	~~!Staining with IHC marker~~
	\|-
	~~\|ASCL1~~
	~~\| 55%~~
	~~\| 73%~~
	\|-
	~~\|NEUROD1~~
	~~\| 27%~~
	~~\| 63%~~
	\|-
	~~\|POU2F3~~
	~~\| 10%~~
	~~\| 15%~~
	\|-
	~~\|YAP1~~
	~~\| 0%~~
	~~\| 3%~~
	\|}

	~~Based on Baine ''et al.''~~:<ref name=pmid33011388>{{cite journal \|authors=Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N \|title=SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization \|journal=J Thorac Oncol \|volume=15 \|issue=12 \|pages=1823–1835 \|date=December 2020 \|pmid=33011388 \|pmc=8362797 \|doi=10.1016/j.jtho.2020.09.009 \|url=}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	! IHC grouping		! IHC grouping